These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8162409)

  • 1. MHC-binding motifs and the design of peptide-based vaccines.
    Ogasawara K; Onoé K
    Trends Microbiol; 1993 Oct; 1(7):276-9. PubMed ID: 8162409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the agretopic residues of a peptide co-restricted to different class II isotypes, I-Au and I-Eu, and its application for preparation of a synthetic peptide vaccine against influenza virus A/Aichi/2/68.
    Takami K; Ogasawara K; Itoh Y; Kajino K; Naruse H; Onoé K
    Microbiol Immunol; 1994; 38(10):779-87. PubMed ID: 7532781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strategy for making synthetic peptide vaccines.
    Ogasawara K; Naruse H; Itoh Y; Gotohda T; Arikawa J; Kida H; Good RA; Onoé K
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):8995-9. PubMed ID: 1409595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of infection of influenza virus in DQ6 mice, a human model, by a peptide vaccine prepared according to the cassette theory.
    Matsuki N; Ogasawara K; Takami K; Namba K; Takahashi A; Fukui Y; Sasazuki T; Iwabuchi K; Good RA; Onoé K
    Vaccine; 1999 Mar; 17(9-10):1161-8. PubMed ID: 10195628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of synthetic peptide vaccine against influenza--T cell epitope the hemagglutinin of A/Aichi/2/68(H3N2) influenza virus induced immune response in mice].
    Naruse H
    Hokkaido Igaku Zasshi; 1994 Jul; 69(4):811-20. PubMed ID: 7525436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
    Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
    Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory.
    Naruse H; Ogasawara K; Takami K; Kajino K; Gotohda T; Itoh Y; Miyazaki T; Good RA; Onoè K
    Vaccine; 1994 Jul; 12(9):776-82. PubMed ID: 7526571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years.
    Naruse H; Ogasawara K; Kaneda R; Hatakeyama S; Itoh T; Kida H; Miyazaki T; Good RA; Onoé K
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9588-92. PubMed ID: 7937811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo.
    Carayanniotis G; Vizi E; Parker JM; Hodges RS; Barber BH
    Mol Immunol; 1988 Sep; 25(9):907-11. PubMed ID: 2850498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity.
    Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V
    J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An investigation of the effect of H3-H3 peptide vaccine for preventing influenza virus infection in DQ6 mice].
    Matsuki N
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):171-9. PubMed ID: 9612710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites.
    Rajnavölgyi E; Horváth A; Gogolák P; Tóth GK; Fazekas G; Fridkin M; Pecht I
    Eur J Immunol; 1997 Dec; 27(12):3105-14. PubMed ID: 9464794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
    Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
    J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orientating peptide residues and increasing the distance between pockets to enable fitting into MHC-TCR complex determine protection against malaria.
    Cifuentes G; Espejo F; Vargas LE; Parra C; Vanegas M; Patarroyo ME
    Biochemistry; 2004 Jun; 43(21):6545-53. PubMed ID: 15157087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules.
    Harris DP; Vordermeier HM; Arya A; Moreno C; Ivanyi J
    Immunology; 1995 Apr; 84(4):555-61. PubMed ID: 7790029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.
    Andreatta M; Karosiene E; Rasmussen M; Stryhn A; Buus S; Nielsen M
    Immunogenetics; 2015 Nov; 67(11-12):641-50. PubMed ID: 26416257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-influenza peptide vaccine in aged mice.
    Ben-Yedidia T; Abel L; Arnon R; Globerson A
    Mech Ageing Dev; 1998 Aug; 104(1):11-23. PubMed ID: 9751429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.